Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients

This publication has 19 references indexed in Scilit:

• BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
  Blood Cancer Journal, 2015
• Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis
  Blood Cancer Journal, 2014
• Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients
  Haematologica, 2014
• Targeting the BRAF V600E Mutation in Multiple Myeloma
  Cancer Discovery, 2013
• Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
  Blood, 2012
• Initial genome sequencing and analysis of multiple myeloma
  Nature, 2011
• BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
  Molecular Cancer Therapeutics, 2011
• Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non‐functional variant transcript
  British Journal of Haematology, 2003
• High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
  New England Journal of Medicine, 2003
• Mutations of the BRAF gene in human cancer
  Nature, 2002